James Clark Appointed CTO of PredictImmune

LG Thin-Clients Feature Built-in RFID Capabilities Optimized for Use in Healthcare Facilities

Supporting its mission to help healthcare providers streamline operations and deliver exceptional patient care, LG Business Solutions USA introduced a new LG thin client...

Experien Group Acquired by Veranex

Veranex combines product development, regulatory, and market access expertise — globally and across complex and emerging markets.

James Clark has been appointed Chief Technical Officer of PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases. The news was announced today.

Previously CEO of EnteroBiotix, specialists in the development of microbiome modulating therapeutics, James has extensive c-suite level experience in the development and commercialization of diagnostic and therapeutic products. Prior to EnteroBiotix James’ roles included Vice President of Clinical Laboratory Operations at Inivata, Chief Technology Officer at Enterome, Vice President of Research & Development at MDxHealth SA and Chief Operating Officer at Response Genetics (IPO: NASDAQ).

Paul Kinnon, CEO, PredictImmune commented on the appointment: “I am delighted to welcome James to the growing team at PredictImmune. His strong scientific background and extensive product development experience is invaluable as we continue to develop PredictSURE IBD™, the world’s first validated and CE-marked prognostic test for guiding treatment options in inflammatory bowel disease and, in addition, accelerate the development of new products in immune-mediated diseases such as Systemic Lupus Erythematosus and multiple sclerosis.”

James Clark, CTO, PredictImmune added: “I am very much looking forward to working with the highly experienced team at PredictImmune to bring the right treatment, to the right patient at the right time. The company’s product pipeline for immune-mediated disease is potentially game-changing for those patients living with these diseases. It’s a very exciting time to be joining the team.”

This latest appointment to the PredictImmune senior team follows a wave of recent announcements including the start of a jointly sponsored study with the Crohn’s & Colitis Foundation to validate PredictSURE IBD™ in the US market, and an announcement that PredictImmune has entered into an exclusive commercial partnership with KSL Biomedical to promote and provide PredictSURE IBD™ throughout North America. Earlier in the year PredictImmune confirmed a strategic agreement with French diagnostic specialist, Theradiag, to commercialize PredictSURE IBD™ in France, Belgium, Luxembourg, Switzerland, and the Maghreb countries. This flurry of activity follows in the wake of the successful launch of PredictSURE IBD™ in the UK and Ireland in April this year.

 

spot_img

DON'T MISS

Graham Belgrave Named to the 2021 PharmaVOICE 100 List of Distinguished Leaders

At Advanced Clinical, and from previous organizations, Belgrave serves as a mentor to several colleagues, where he challenges them to think outside of the box and take risks.

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.